The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies.
A. J. Spencer, S. Morris, M. Ulaszewska, C. Powers, R. Kaliath, C. D. Bissett, A. Truby, N. Thakur, J. Newman, E. R. Allen, I. Rudiansyah, C. Lui, W. Dejnirattisai, J. Mongkolsapaya, H. Davies, , T. Lambe
bioRxiv · Jun 8, 2021Immunology